Nectar Lifesciences Share Price Today | Stock Price & Nectar Lifesciences Share Screener
As of October 5, 2026, the live Nectar Lifesciences share price (NSE: NECLIFE) is ₹10.48 on NSE and ₹10.57 on BSE, up 2.44% from the previous close, with shares trading between ₹10.18 and ₹10.58 in today's trading session, and a 52-week range of ₹9.30–₹20.95. Check NECLIFE 52-week performance for the annual price range and momentum. Use the Nectar Lifesciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Nectar Lifesciences opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹3 and net income of ₹-15, with EBITDA of ₹-25, an operating margin of -277000.0% and a profit margin of -500.0%.
Nectar Lifesciences Share Price Chart
Track the current stock price of Nectar Lifesciences with an interactive chart. Analyse NECLIFE share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Nectar Lifesciences stock quote in one place.
The quote of ₹10.48 sits between the 52-week low of ₹9.30 and the 52-week high of ₹20.95, and the latest session moved 2.44% from the previous close.
Nectar Lifesciences Company Profile - Fundamental Screener
Screen Nectar Lifesciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for NECLIFE shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE023H01027.
Company Details
Classification
Identifiers and Leadership
Nectar Lifesciences Balance Sheet Screener
Screen NECLIFE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹622, down from ₹2,047 in 2025.
Latest statistics put total assets at ₹622 and shareholder funds at ₹582, with a leverage ratio of 0.38.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 622 | 2,047 | 2,191 | 2,189 | 2,391 | 2,471 | 2,633 | 2,705 | 2,724 | 2,581 |
| Current Assets | 253 | 1,238 | 1,284 | 1,231 | 1,355 | 1,239 | 1,615 | 1,669 | 1,661 | 1,496 |
| Fixed Assets | 105 | 633 | 643 | 662 | 723 | 772 | 785 | 825 | 852 | 881 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 13 | 70 | 149 | 234 | 299 | 222 | 249 | 300 | 356 | 296 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 582 | 956 | 1,069 | 1,065 | 1,088 | 1,062 | 1,136 | 1,105 | 1,059 | 1,007 |
| Share Capital | 19 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
| Reserves & Surplus | 563 | 934 | 1,047 | 1,042 | 1,066 | 1,040 | 1,114 | 1,083 | 1,036 | 984 |
Nectar Lifesciences Income Statement Screener - Profit & Revenue Analysis
Screen Nectar Lifesciences income statement and profit fundamentals. Analyze NECLIFE quarterly results. Nectar Lifesciences reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Jun, revenue was ₹3 and net profit was ₹-15, equal to earnings per unit of ₹-0.79, at an operating margin of -277000%.
In that period expenses were ₹28, interest cost ₹0 and tax ₹-9. The next period listed, 2026-Mar, shows revenue of ₹6 and net profit of ₹-68.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 3 | 6 | 36 | 0 | 6 | 0 | 8 | 12 | 359 | 441 | 453 | 409 | 395 | 406 | 357 |
| Expenses | 28 | 89 | 2 | 177 | 69 | 130 | 0 | 6 | 320 | 393 | 410 | 371 | 359 | 371 | 343 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | -25 | -83 | 34 | -176 | -63 | -130 | 8 | 6 | 40 | 49 | 43 | 38 | 36 | 35 | 15 |
| Operating Profit % | -277000.00% | 0.00% | 0.00% | 0.00% | -1212.00% | 0.00% | 0.00% | -10.00% | 11.00% | 11.00% | 9.00% | 7.00% | 9.00% | 4.00% | 0.00% |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 16 | 15 | 15 | 15 | 15 | 15 | 15 |
| Interest | 0 | 6 | 30 | 0 | 0 | 0 | 0 | 0 | 20 | 24 | 25 | 21 | 18 | 20 | 18 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | -24 | -88 | 3 | -176 | -64 | -130 | 8 | 6 | 5 | 11 | 3 | 2 | 3 | 2 | -18 |
| Tax | -9 | -20 | -11 | 0 | 0 | 0 | 0 | 0 | 2 | 11 | 1 | 1 | 1 | -2 | -8 |
| Net Profit | -15 | -68 | 14 | -176 | -63 | -130 | 8 | 6 | 3 | 1 | 2 | 1 | 2 | 4 | -9 |
| EPS | -0.79 | -3.38 | 0.64 | -7.85 | -2.82 | -5.80 | 0.35 | 0.25 | 0.13 | 0.03 | 0.07 | 0.05 | 0.08 | 0.16 | -0.41 |
Nectar Lifesciences Cash Flow Screener - Liquidity Fundamentals
Screen NECLIFE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities used ₹349, and net cash flow was an inflow of ₹93.
Over the same period, investing activities provided ₹1,208 and financing activities used ₹767.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | -349 | 169 | 225 | 134 | 95 | 21 | 285 | 239 | 65 | 199 |
| Investing Activities | 1,208 | -42 | -17 | 52 | 17 | -29 | -33 | -26 | -29 | -18 |
Financing and Net Cash | ||||||||||
| Financing Activities | -767 | -128 | -205 | -186 | -119 | 12 | -252 | -201 | -40 | -204 |
| Net Cash Flow | 93 | -1 | 2 | 0 | -8 | 4 | 0 | 12 | -4 | -24 |
Nectar Lifesciences Shareholding Pattern Screener
See Nectar Lifesciences shareholding pattern with promoter, FII, and DII holdings. Check Nectar Lifesciences promoter holding and ownership changes for NECLIFE on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Jan, promoters held 51.84%, foreign institutions 0.58%, domestic institutions 3.54% and the public 35.83%, spread across 76,648 shareholders.
The shareholder count was 76,648 in 2026-Jan, compared with 74,834 in 2026-Mar.
| Item | 2026-Jan | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 51.84% | 51.84% | 51.84% | 44.53% | 44.53% | 44.91% | 44.91% | 55.80% |
Institutional Investors | ||||||||
| FII Holding | 0.58% | 0.60% | 0.50% | 1.65% | 0.81% | 0.62% | 0.52% | 16.97% |
| DII Holding | 3.54% | 4.01% | 3.74% | 0.16% | 0.19% | 0.09% | 5.82% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% |
| Public Holding | 35.83% | 36.23% | 37.58% | 41.60% | 44.12% | 44.70% | 39.72% | 23.32% |
| Other Holding | 8.18% | 7.29% | 6.32% | 12.04% | 10.32% | 9.67% | 9.00% | 3.88% |
| Shareholder Count | 76,648 | 74,834 | 73,834 | 69,241 | 71,977 | 76,470 | 78,124 | 59,946 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Nectar Lifesciences. Nectar Lifesciences dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.05 | 0.27% |
| 2019-March | ₹0.05 | 0.51% |
| 2018-March | ₹0.05 | 0.29% |
| 2017-March | ₹0.05 | 0.19% |
Nectar Lifesciences Stock Index Membership - Nifty & Sensex
See which indices include Nectar Lifesciences stock. Check NECLIFE index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Nectar Lifesciences Market Events Screener - Corporate Actions
Get Nectar Lifesciences corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Nectar Lifesciences stock events that may affect NECLIFE share price, along with derivatives, futures and options activity and sector gainers.
13 corporate actions are listed, the most recent entry being Annual General Meeting dated September 18, 2026, with a record date of September 18, 2026.
It is followed by Quarterly Result Announcement dated August 14, 2026 and Quarterly Result Announcement dated May 30, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-18 | 2026-09-18 | Annual General Meeting | NA | 4.32% |
| 2026-08-14 | 2026-08-14 | Quarterly Result Announcement | NA | 7.18% |
| 2026-05-30 | 2026-05-30 | Quarterly Result Announcement | NA | 2.64% |
| 2026-01-23 | 2026-01-23 | Quarterly Result Announcement | NA | -4.39% |
| 2025-12-24 | 2026-12-31 | Buyback | 27 | -2.67% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 8.67% |
| 2025-09-29 | 2025-09-29 | Annual General Meeting | NA | -5.38% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | 8.63% |
| 2025-08-04 | 2025-08-04 | Extraordinary General Meeting | NA | -28.60% |
| 2025-07-07 | 2025-07-07 | Quarterly Result Announcement | NA | -9.14% |
| 2025-01-31 | 2025-01-31 | Quarterly Result Announcement | NA | -18.01% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -11.31% |
| 2024-09-21 | 2024-09-21 | Annual General Meeting | NA | 41.10% |
Nectar Lifesciences Competitors Screener - Peer Stocks Comparison
Screen NECLIFE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 427,010 | 35.84 | 61,674 | 12.69% | 11,565 | 33.78 |
| Divis Laboratories | 244,125 | 84.36 | 11,067 | 13.95% | 2,568 | 49.73 |
| Torrent Pharmaceuticals | 181,512 | 84.01 | 13,886 | 20.34% | 2,138 | 41.48 |
| Zydus Life Science | 113,616 | 24.88 | 27,658 | 17.64% | 5,026 | 46.18 |
| Cipla | 107,890 | 32.42 | 29,045 | 2.24% | 3,870 | 32.87 |
| Laurus Labs | 106,517 | 98.56 | 6,868 | 22.01% | 890 | 56.11 |
| Mankind Pharma | 102,394 | 50.48 | 14,636 | 14.85% | 1,938 | 55.53 |
| Dr Reddys Laboratories | 100,412 | 31.47 | 35,059 | 3.90% | 4,158 | 52.91 |
| Aurobindo Pharma | 96,370 | 25.97 | 34,145 | 5.56% | 3,503 | 49.89 |
| Lupin | 91,961 | 16.71 | 29,039 | 26.75% | 5,356 | 29.12 |
Nectar Lifesciences Company Announcements - News & Reports Screener
Screen NECLIFE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated .
The next most recent announcements are dated October 4, 2026 and September 24, 2026.
| Date | Update | Actions |
|---|---|---|
| Minutes Of 31St Annual General Meeting ("AGM") | - | |
| 2026-10-04 | Disclosure As Per Regulation 30 Of The Securities And Exchange Of Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-09-24 | Closure of Trading Window | - |
| 2026-09-19 | Revised Proceedings Of 31St Annual General Meeting (AGM) | - |
| 2026-09-18 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-18 | Proceedings Of 31St Annual General Meeting (AGM) | - |
| 2026-08-22 | Letter Sent To Members | - |
| 2026-08-21 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-20 | Reg. 34 (1) Annual Report. | - |
| 2026-08-20 | Notice Of 31St Annual General Meeting (AGM) For The Financial Year 2025-26 | - |
| 2026-08-20 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-15 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-15 | Announcement under Regulation 30 (LODR)-Change in Corporate Office Address | - |
| 2026-08-14 | Book Closure/ Cut-Off Date For The Purpose Of 31St Annual General Meeting (AGM) For The Financial Year (FY) 2025-26 | - |
| 2026-08-14 | Board Meeting Outcome for 31St Annual General Meeting ("AGM") To Be Held On 18-09-2026 And Other Business Matters. | - |
| 2026-08-14 | Unaudited Standalone And Consolidated Financial Results For The Quarter Ended On June 30 2026 | - |
| 2026-08-10 | Board Meeting Intimation for Financial Results And Other Business Matters. | - |
| 2026-08-06 | Announcement under Regulation 30 (LODR)-Resignation of Director | - |
| 2026-08-04 | Sale And Surrender Of Leasehold Rights In Land Situated In Jammu | - |
| 2026-07-23 | Update On Slump Sale | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹10.48, within a 52-week range of ₹9.30 to ₹20.95. The P/E ratio is -0.82 and the P/B ratio is 0.34, with earnings per unit of ₹-13.40. Market capitalisation stands at ₹203.59 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.